Elsevier

Biochimie

Volume 95, Issue 11, November 2013, Pages 1971-1979
Biochimie

Review
Ectopic lipid accumulation: A potential cause for metabolic disturbances and a contributor to the alteration of kidney function

https://doi.org/10.1016/j.biochi.2013.07.017Get rights and content

Highlights

  • Ectopic lipid accumulation plays an important role in insulin resistance.

  • This phenomenon is referred to as lipotoxicity.

  • Insulin resistance is a common feature in Chronic Kidney Disease (CKD).

  • Lipotoxicity contributes to insulin resistance associated with CKD.

Abstract

Ectopic lipid accumulation is now known to be a mechanism that contributes to organ injury in the context of metabolic diseases. In muscle and liver, accumulation of lipids impairs insulin signaling. This hypothesis accounts for the mechanism of insulin resistance in obesity, type 2 diabetes, aging and lipodystrophy. Increasing data suggest that lipid accumulation in the kidneys could also contribute to the alteration of kidney function in the context of metabolic syndrome and obesity. Furthermore and more unexpectedly, animal models of kidney disease exhibit a decreased adiposity and ectopic lipid redistribution suggesting that kidney disease may be a state of lipodystrophy. However, whether this abnormal lipid partitioning during chronic kidney disease (CKD) may have any functional impact in these tissues needs to be investigated.

Here, we provide a perspective by defining the problem and analyzing the possible causes and consequences. Further human studies are required to strengthen these observations, and provide novel therapeutic approaches.

Introduction

There is an epidemic of obesity and the metabolic syndrome (Met-S) across the world. Both entities are associated with high mortality, mainly as a result of cardiovascular diseases. Several hypotheses including excessive visceral fat deposition have been postulated to explain the metabolic abnormalities in obesity and insulin resistance state. The combination of sedentary life style with ready to eat energy rich food in genetically susceptible individuals predisposes persistently over-nourished individuals to gain weight, and when the energy intake exceeds the storage capacity of subcutaneous white adipose tissue (WAT) [1], [2], it induces lipid accumulation in ectopic sites. Non-alcoholic fatty liver disease (NAFLD) is now the most common chronic liver disease in the world with a prevalence of 20–30% in the general population. It is associated with hepatic insulin resistance and is a risk factor for the development of type 2 diabetes [3], [4], [5]. Interestingly, lipid accumulation in ectopic sites is also a characteristic feature of lipodystrophy, a metabolic disorder in which adipose tissue looses its ability to buffer postprandial influx of fatty acids (FA) [6]. Furthermore, lipid accumulation in muscle and liver contributes also to the age-induced insulin resistance and seems related to the associated impaired mitochondrial function [7], [8]. A strong relationship between glucose and lipid metabolism has been recognized for decades. Indeed, the pioneering studies of Randle et al. postulated that FA could impair insulin stimulated glucose oxidation in muscle [9], [10]. They showed that under fasting condition, lipolysis and the resultant increase in circulating non-esterified fatty acids (NEFA) contribute to the increased reliance on fat oxidation to provide energy, and the generation of fat oxidation by-products suppresses glucose oxidation.

The most common cause of progressive kidney disease in the developed world is diabetic nephropathy (DN), microalbuminuria being one of its earliest manifestations. Albuminuria in DN has been considered to be predominantly a consequence of hyperglycemia and glomerular hyperfiltration. However, microalbuminuria also occurs in non-diabetic insulin resistant subjects in whom it is an independent risk factor for cardiovascular disease [11]. This last decade, studies have shown that lipid accumulation in the kidney may also be the cause of Met-S associated renal injury [12], [13].

Emerging evidence suggests that chronic kidney disease might be a state of acquired lipodystrophy leading to ectopic lipid deposition (i.e. lipid deposition in non-adipose tissues). It is known for decades that chronic kidney disease (CKD) induces dyslipidemia with increased plasma triglycerides. While most studies have focused on the impaired clearance of triglyceride rich lipoproteins in the course of CKD [14], recent studies show that adipose tissue flexibility might be altered during CKD resulting in a loss of white adipose tissue (WAT) and the accumulation of lipids in ectopic sites [15], [16]. In fact, increased visceral fat accumulation as assessed by abdominal computed tomography has been shown in non-diabetic hemodialysis patients compared to controls despite lower body mass index (BMI) [17]. There are reasons to believe that this is an important issue to address, because estimation of body fat content with BMI may not adequately reflect the amount of atherogenic visceral and ectopic adipose tissue specifically in the CKD patients [18]. Most importantly, emerging evidence point toward an important role of ectopic fat accumulation in the pathophysiology of insulin resistance and the associated comorbidities [19].

In the present review, we will address the causes and potential impacts of ectopic lipid accumulation in the context of metabolic diseases with emphasis on its potential mechanisms and consequences during the course of CKD.

Section snippets

Energy imbalance

The most common cause in Western society can be attributed to chronic energy imbalance with energy intake exceeding energy expenditure, and increased substrate delivery to peripheral organs. White adipose tissue (WAT) plays a central role in the management of systemic energy stores as well as in many other processes. Healthy humans respond to excess energy intake by storing this surplus of calories as triglycerides in WAT. In obesity state, energy intake exceeds the storage capacity of adipose

Potential mediators of cellular dysfunction related to ectopic fat accumulation

Lipotoxic cellular dysfunctions and injuries occur through several mechanisms, including the generation of reactive oxygen species (ROS), multiple organellar damage, disruption of intracellular signaling pathways, release of proinflammatory and profibrotic factors, and lipid-induced apoptosis. Excess intracellular NEFA and their metabolites (FA-CoA, DAG, and ceramides) promote insulin resistance and exert deleterious effects on various organs [22], [31].

Liver: hepatic steatosis and insulin resistance

Ectopic lipid accumulation in the liver is now widely known as NAFLD [22] and is closely associated with obesity, insulin resistance, and type 2 diabetes mellitus. In the case of hepatic steatosis, hepatic insulin resistance is associated with decreased insulin-stimulated insulin receptor substrate-2 (IRS-2) tyrosine phosphorylation, leading to the inability of insulin to activate hepatic glycogen synthesis and suppress hepatic glucose production. This hepatic insulin resistance is associated

Potential mechanisms: adipose tissue dysfunction

Experimental CKD is associated with reduction of fat depot sizes, and ectopic lipid redistribution [15], [91], [92]. This is also a common phenomenon associated with aging and lipodystrophic syndromes [6], [7] and could be a key factor in the development of metabolic disorders. Since adipocyte size and number are related to insulin sensitivity, glucose and fatty acid uptake and cytokine release, changes in function and cellular composition of WAT might lead to changes in metabolic state and

Conclusion

Ectopic lipid accumulation in visceral tissues including the kidneys is a common finding in models of metabolic diseases but also in kidney diseases. Lipotoxicity has been proven to account for major manifestations of the Met-S in liver, muscle, heart as well as pancreas. Increasing evidence suggests that it may contribute to kidney cell dysfunction and organ injury. Understanding the pathogenesis of lipid mediated renal and vascular injury will provide new targets for therapeutic intervention.

Disclosure statement

None.

Acknowledgments

The authors gratefully acknowledge Dr. Nicolas J PILLON (The Hospital for Sick Children, University of Toronto, Canada) who kindly allows them the free use of his figure of insulin signaling pathways.

References (121)

  • C. Yu et al.

    Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle

    J. Biol. Chem.

    (2002)
  • T.E. Fox et al.

    Ceramide recruits and activates protein kinase C zeta (PKC zeta) within structured membrane microdomains

    J. Biol. Chem.

    (2007)
  • M. Cnop et al.

    Endoplasmic reticulum stress, obesity and diabetes

    Trends Mol. Med.

    (2012)
  • S. Ranjit et al.

    Regulation of fat specific protein 27 by isoproterenol and TNF-α to control lipolysis in murine adipocytes

    J. Lipid Res.

    (2011)
  • M.T.A. Nguyen et al.

    JNK and tumor necrosis factor-alpha mediate free fatty acid-induced insulin resistance in 3T3-L1 adipocytes

    J. Biol. Chem.

    (2005)
  • M.T.A. Nguyen et al.

    A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways

    J. Biol. Chem.

    (2007)
  • H. Kumar et al.

    Toll-like receptors and innate immunity

    Biochem. Biophys. Res. Commun.

    (2009)
  • V.T. Samuel et al.

    Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease

    J. Biol. Chem.

    (2004)
  • C. Schmitz-Peiffer

    Signalling aspects of insulin resistance in skeletal muscle: mechanisms induced by lipid oversupply

    Cell. Signal

    (2000)
  • M. Shimabukuro et al.

    Lipoapoptosis in beta-cells of obese prediabetic fa/fa rats. Role of serine palmitoyltransferase overexpression

    J. Biol. Chem.

    (1998)
  • C.L. Kelpe et al.

    Palmitate inhibition of insulin gene expression is mediated at the transcriptional level via ceramide synthesis

    J. Biol. Chem.

    (2003)
  • C. Schmitz-Peiffer et al.

    Inhibition of PKCepsilon improves glucose-stimulated insulin secretion and reduces insulin clearance

    Cell Metab.

    (2007)
  • K. Iseki et al.

    Body mass index and the risk of development of end-stage renal disease in a screened cohort

    Kidney Int.

    (2004)
  • Y. Wang et al.

    Association between obesity and kidney disease: a systematic review and meta-analysis

    Kidney Int.

    (2008)
  • C. Tsioufis et al.

    Relation of microalbuminuria to adiponectin and augmented C-reactive protein levels in men with essential hypertension

    Am. J. Cardiol.

    (2005)
  • L. Sun et al.

    Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus

    J. Biol. Chem.

    (2002)
  • T. Jiang et al.

    Diet-induced obesity in C57BL/6J mice causes increased renal lipid accumulation and glomerulosclerosis via a sterol regulatory element-binding protein-1c-dependent pathway

    J. Biol. Chem.

    (2005)
  • Y. Tanaka et al.

    Fenofibrate, a PPARα agonist, has renoprotective effects in mice by enhancing renal lipolysis

    Kidney Int.

    (2011)
  • M. Soumura et al.

    Oleate and eicosapentaenoic acid attenuate palmitate-induced inflammation and apoptosis in renal proximal tubular cell

    Biochem. Biophys. Res. Commun.

    (2010)
  • G.I. Welsh et al.

    Insulin signaling to the glomerular podocyte is critical for normal kidney function

    Cell Metab.

    (2010)
  • C.C. Pelletier et al.

    White adipose tissue overproduces the lipid-mobilizing factor zinc α2-glycoprotein in chronic kidney disease

    Kidney Int.

    (2013)
  • G. Murdolo et al.

    The dysregulated adipose tissue: a connecting link between insulin resistance, type 2 diabetes mellitus and atherosclerosis

    Nutr. Metab. Cardiovasc. Dis.

    (2006)
  • S. Virtue et al.

    Adipose tissue expandability, lipotoxicity and the metabolic Syndrome—an allostatic perspective

    Biochim. Biophys. Acta

    (2010)
  • E. Kalbacher et al.

    Human uremic plasma and not urea induces exuberant secretion of leptin in 3T3-L1 adipocytes

    J. Ren. Nutr.

    (2011)
  • T. Roubicek et al.

    Increased production of proinflammatory cytokines in adipose tissue of patients with end-stage renal disease

    Nutrition

    (2009)
  • N.D. Vaziri et al.

    Down-regulation of hepatic LDL receptor expression in experimental nephrosis

    Kidney Int.

    (1996)
  • J.E. Galgani et al.

    Metabolic flexibility and insulin resistance

    Am. J. Physiol. Endocrinol. Metab.

    (2008)
  • N. Kumashiro et al.

    Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease

    Proc. Natl. Acad. Sci. U. S. A

    (2011)
  • E. Fabbrini et al.

    Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity

    Proc. Natl. Acad. Sci. U. S. A

    (2009)
  • A. Garg

    Clinical review#: lipodystrophies: genetic and acquired body fat disorders

    J. Clin. Endocrinol. Metab.

    (2011)
  • K.F. Petersen et al.

    Mitochondrial dysfunction in the elderly: possible role in insulin resistance

    Science

    (2003)
  • P.J. Randle

    Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years

    Diabetes Metab. Rev.

    (1998)
  • J.T. Lane

    Microalbuminuria as a marker of cardiovascular and renal risk in type 2 diabetes mellitus: a temporal perspective

    Am. J. Physiol. Renal. Physiol.

    (2004)
  • S. Kume et al.

    Role of altered renal lipid metabolism in the development of renal injury induced by a high-fat diet

    J. Am. Soc. Nephrol.

    (2007)
  • Z. Li et al.

    Increased glomerular filtration rate in early metabolic syndrome is associated with renal adiposity and microvascular proliferation

    Am. J. Physiol. Renal. Physiol.

    (2011)
  • N.D. Vaziri et al.

    Lipoprotein lipase deficiency in chronic kidney disease is accompanied by down-regulation of endothelial GPIHBP1 expression

    Clin. Exp. Nephrol.

    (2012)
  • H.-L. Zhao et al.

    Lipid partitioning after uninephrectomy

    Acta Diabetol.

    (2011)
  • M. Odamaki et al.

    Altered abdominal fat distribution and its association with the serum lipid profile in non-diabetic haemodialysis patients

    Nephrol. Dial. Transplant.

    (1999)
  • C. Zoccali et al.

    Assessment of obesity in chronic kidney disease: what is the best measure?

    Curr. Opin. Nephrol. Hypertens.

    (2012)
  • B.J. Arsenault et al.

    Mapping body fat distribution: a key step towards the identification of the vulnerable patient?

    Ann. Med.

    (2012)
  • Cited by (0)

    View full text